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This paper deals with comparative sequential studies of serum 7-glutamyl transpeptidase and serum 5'-nucleotidase and serum alanine
aminotransferase in cancer patients.
The levels of 7-glutamyl transpeptidase and 5'-nucleotidase, as indicators of metastatic liver, take approximately parallel courses. The
levels of 7-glutamyl transpeptidase do not rise earlier than the levels of S'-nucleotidase but may rise to a greater extent in some cases.
Strong increases of τ-glutamyl transpeptidase occur in cases of hepatotoxic liver damage as a consequence of therapy. In a number of
cases 7-glutamyl transpeptidase was the only serum enzyme studied that did increase. Increases of τ-glutamyl transpeptidase as a res-
ponse to therapy might overshadow any response of 7-glutamyl transpeptidase due to the course of malignant process.
• \
In vergleichenden Untersuchungen wird das Verhalten von 7-Glutamyl-Transpeptidase, S'-Nucleotidase und Alantoaminotransferase im
Serum von Krebspatienten mit dem klinischen Verlauf in Beziehung gesetzt. Soweit die Aktivit t der 7-Glutamyl-Transpeptidase ein
Indikator von Metastasen in der Leber ist, l uft sie parallel mit der Aktivit t der S'-Nucleotidase. Die 7-Glutomyl-Transpeptidase^Aktivi-
tat steigt nicht eher als die S'-Nucleotidase-Aktivit t, aber manchmal steigt sie ber die der S'-Nucleotidase hinaus. Starke Erh hungen
von 7-Glutamyl-Transpeptidase treten bei toxischen Lebersch den infolge therapeutischer Verfahren auf. In vielen solchen F llen war
die 7-Glutamyl-Transpeptidase das einzige erh hte Serumenzym. Diese Reaktion der τ-Glutamyl-Transpeptidase erschwert in hohem
Ma e die Brauchbarkeit der 7-Glutamyl-Transpeptidase f r die klinische Bewertung der Therapie.
Elevation of the serum activity of several enzymes1) has
been claimed to be an indication of metastatic processes
in the liver. Interest was first focussed on transaminases
and alkaline phosphatase for this purpose. In more recent
years 5f-nucleotidase and γ-glutamyl transpeptidase have
also been used for the detection of malignant liver
disease. The advantages of S'-nucleotidase as a diagnostic
tool have been summarized in reference (1). γ-Glutamyl
transpeptidase has been reported to be increased in
patients suffering from metastatic liver (2, 3, 4, 5, 6).
This has also been observed with 5'-nucleotidase (1, 7).
It has been suggested that γ-glutamyl transpeptidase may
replace S'-nucleotidase for confirming the hepatic origin
of raised alkaline phosphatase (8). Preliminary obser-
vations however indicated that γ-glutamyl transpepti-
dase may not have the same reaction pattern as S'-nuc-
leotidase in malignant liver disease. Therefore an attempt
was made to determine the clinical significance of va-
riations of γ-glutamyl transpeptidase in cancer patients.
1) Enzymes
S'-nucleotidase = S'-Ribonucleotide phosphohydrolase (EC
3.1.3.5.); 7-glutamyl transpeptidase: Not listed in the report
of the International Union of Biochemistry (Elsevier,
Amsterdam, 1964); alanine aminotransferase = Ζ,-Alanine: ·
2-oxo-glutarate aminotransferase (EC 2.6.1.2.); alkaline
phosphatase = Orthophosphoric monoester phosphohydro-
lase (EC 3.1.3.1.).
For this purpose the levels of γ-glutamyl transpeptidase
were compared with those of S'-nucleotidase, whose
clinical value has been established by various studies
(1,7,9).
Attention was paid to the following questions:
a) Are γ-glutamyl transpeptidase activities elevated
earlier and in more cases of confirmed metastatic
liver than S'-nucleotidase activities.
b) What is the influence of hepatotoxic therapy on the
levels of γ-glutamyl transpeptidase.
Materials and methods
7-Glutamyl transpeptidase
This enzyme was sometimes assayed according to a manual
procedure (10) but in most cases by an automated procedure.
Both procedures use r-glutamyl-p-nitroanilide as a substrate.
The newly developed flow diagram for the automated pro-
cedure is given in figure 1 (1:2 sample/wash ratio). Forty
specimens were run per hour. Two heating coils were placed in
sequence in order to obtain an incubation time of 13 minutes.
The solutions containing the buffer and the substrate were
prepared according to Szasz (11) and contained 0.1% (v/v)
sterox sulution. The fluid stream containing the liberated
p-nitroaniline was allowed to pass from one part of the system
to another through glass tubing. Calibration curves were con-
structed using pooled sera with different levels of activity as
standards. These levels were established by the manual method
(ref. 10, with the exception that incubation was performed
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Fig. 1. Flow diagram for the assay of τ-glutamyl transpeptidase.
at 37° C). Use of semilog graph paper simplified the check of
linearity of recorded absorbances against activities of the stan-
dards during each run. Every tenth specimen was a control
of known activity. To prepare control specimens the activity
of a pooled serum was measured with the manual procedure.
Thereafter aliquots were stored at - 20° C. Standards were
also kept frozen. Standards and controls were used only once
after thawing. The coefficient of variation of the controls
prepared from random sampled sera during one month was
3.8% (mean 85U/1, n = 89).
Comparison of the automated method with the manual
method showed a correlation coefficient (r) of r = 0.9917
Normal values: males 6-38 U/l; females 4-24 U/l. The
coefficient of variation was found to be 1.5 % in the range of
slightly elevated values.
5'-Nucleotidase
The procedure as described in ref. 13 was followed.
For comments on the procedure the reader should consult
references 7,14,15 and 16. Normal values 5.5-11.5 U/l
(37°C). The coefficient of variation is 3.5% (see ref. 13) in
the range of slightly elevated values.
Alanine am inotransferase
The assay was performed kineticaily with an LKB reaction
rate analyzer using Boehringer reagent kits (non-optimal
assay adapted for automated analysis). The automatic dis-
penser was set for 100 Ml 2-oxoglutarate solution since
smaller volumes may give erratic results. The oxoglutarate
solution had been diluted so as to obtain the prescribed final
concentration during measurement. Normal range till 24 U/l
(35° C). The coefficient of variation was found to be 2.0%
in the range of slightly elevated values.
Results
7-Glutamyl transpeptidase and 5'-nucleotidase levels
were studied in a group of 33 patients with malignant
liver disease. For 31 patients the presence of liver
metastases was established by laparotomy. For one
patient the probability of metastatic liver was indicated
by liver scintigraphy. For the last patient of this group
the diagnosis of liver carcinoma was made on the basis
of foetoprotein estimation. The primary sites included
breast, stomach, rectum, colon and lymph glands. 7-
Glutamyl transpeptidase and 5'-nucleotidase values
obtained prior to examination by laparotomy etc. are
depicted in figure 2. In the majority of cases no other
therapeutic measures had been performed. The data show
that in 7 cases normal levels of one of the two enzymes
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Fig. 2. Comparison of serum 5'-nucleotidase activities and serum
7-glutamyl transpeptidase activities in cases of confirmed
liver metastases.
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Fig. 3. Variation, with time of γ-glutamyl transpeptidase (o—o)
and 5'-nucleotidase («—·) levels.
were found. In five cases both enzymes had normal
levels.
Study of the sequential course of 5'-nucleotidase and
7-glutamyl transpeptidase in a great number of patients
revealed no clear evidence that the level of γ-ghitamyl
transpeptidase rose before that of 5'-nucleotidase. Both
enzyme activities take a parallel course. Remarkable
deviations were found after the start of hepatotoxic
therapy (see below).
In figure 3 a, 3b and 4 examples are given of the parallel
course of γ-glutamyl transpeptidase and 5'-nucleotidase.
Figure 3 a and b show changes of γ-glutamyl transpepti-
dase and 5'-nucleotidase in two patients suffering from
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M. Hodgkin. The liver was found enlarged at the times
indicated by arrows A, B and D (fig. 3 a). Liver was not
palpable at time C. Liver scintigraphy, performed at
time S, suggested the existence of liver metastases. At
the. time indicated by arrow 0 (fig. 3b) laparotomy
revealed the existence of metastases in the liver, which
was palpable shortly before. Figure 4 may be interesting
since the existence of liver metastases have been con-
firmed at two different times: by laparotomy at time
0 and by autopsy at time B. γ-Glutamyl transpeptidase
and 5'-nucleotidase take parallel courses except for the
short time following laparotomy (see arrow A).
Additional information is given in table 1.
The data in this table refer to patients in which the
existence of metastases in the liver was confirmed by
autopsy. The highest value of each serum enzyme shortly
before death has been used. When assembling data
from laparotomy reports it was found that in 66 cases
the liver had been judged to have a normal aspecht. In
11 of these patients γ-gjutamyl transpeptidase values
were elevated, the 5-nucleotidase values in two of them
were normal. It should perhaps be noted that one of
these two patients (normal 5'-nucleotidase and elevated
γ-ghitamyl transpeptidase) was addicted to palphium.
In the second patient no clinical signs for the existence
of liver metastases became apparent within several
months after laporotomy.
The effect of hepatotoxic therapy on the level of γ-
glutamyl transpeptidase which was referred to above
was studied in the way described in ref. 1. It was found
that the start of a given therapy may cause a transient
or apparently additional rise in the activity of serum
enzymes. The amount of transient increase of serum
activity can vary considerably.
Toxic damage resulted in much greater changes in the
level of γ-gjlutamyl transpeptidase than of 5'-nucleoti-
dase. (The latter phenomenon! has been described
already in ref. 1,7). In 43 cases in which either one
or both serum enzymes showed transient elevations
the following observations were made: Increases of
7-glutamyl transpeptidase to an amount less than
twice the upper normal level were found only in
10 cases. The greatest increase of γ-gUit myl transpepti-
dase was twenty times the upper normal level. In 33
cases the transient rise of the 5'-nucleotidase activity
was between zero and twice the upper normal level.
In 21 cases the rise of S'-nucleotidase was between
zero and the medium normal range. The greatest in-
crease of serum alanine aminotransferase was
23 times the upper normal level. Examples are given
in figure 5 and 6. We give for comparative purposes
the values of alanine aminotransferase, which is a
sensitive monitor for hepatotoxic damage.
Figure 5 a concerns a patient suffering from M. Hodgkin
who was treated with Velbe (at the times indicated
by the left and right arrows). Bleiomycin was given
a few days after the first Velbe treatment. The liver
of the patient was not palpable. Chemotherapy was
continued for two months. The serum enzymes were
seldom determined and gave elevated γ-glutamyl
transpeptidase and normal 5'-nucleotidase values. The *
patient died shortly after. Autopsy did not show the
presence of liver metastases. Figure 5b concerns a
patient with tumour in the flour of the mouth,
which was treated surgically at the time indicated by
the arrow. Note that ^gjhitamyl transpeptidase shows
the strongest reaction to the therapeutic measures.
Tab. 1. Serum 7-glutamyl transpeptidase, 5'-nucleotidase and alanine aminotransferase in cases of metastatic liver confirmed by
autopsy.
*) upper normal level
number of cases within
normal range l-2x*) 2-4x*) 4-8x*) 8-16X*) . >16x*)
5'-nucleotidase
γ-glutamyl transpeptidase
alanine aminotransferase
2
0
10
3
3 ο
3
5
3
3
0
5
5
1
1
4
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Fig. 5. Variation, with time of r-glutamyl transpeptidase (o—o),
S'-nucleotidase (·—·) and alanine aminotransferase
(Δ—Δ) levels.
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Fig. 6. Variation, with time of rglutamyl transpeptidase (o—o),
S'-nucleotidase (·—·) and alanine aminotransferase
(Δ—Δ) levels.
Figure 6 a shows the variation of serum enzymes in a
patient suffering from a breast carcinoma. The liver
was normal on palpation during the period covered in
the abcissa. Within two months after the androgen
therapy the patient's condition improved remarkably.
Serum enzymes remained normal.
Figure 6b shows the serum enzyme levels of a patient
with M. Hodgkin who received a combined chemothe-
rapy. The liver was found to be enlarged before the
onset of the therapy but appeared normal three months
later. This would indicate that the decrease of S'-nucleo-
tidase values reflects regression of malignant processes
in the liver. Note that the course of γ-glutamyl trans-
peptidase parallels the course of alanine aminotrans-
ferase.
If different courses of therapy are given with short
intervals, the sequential responses of serum enzymes
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Fig. 7. Variation, with time of τ-glutamyl transpeptidase (o—o),
5'-nucleotidase (·—·) and alanine aminotransferase
(Δ—Δ) levels. Patient H. The arrow 0 denotes time of
laparotomy.
may overlap. In such cases it is often difficult to
establish that a change of enzyme activity reflects an
extensive hepatotoxic process. An example is given
in figure 7. Patient H (fig. 7) was suffering from breast
carcinoma with metastases in bone, liver and lung. The
liver was found by palpation to be enlarged at the
times indicated by arrows A and C but to be less
enlarged at time B. It will be noted that the course
of γ-glutamyl transpeptidase shows sharp transient
increases after the third and fourth treatments with
5-Fluoro-uracil and Vincristine. The high value of
alanine aminotransferase at the start of the curve is
due to hepatotoxic damage caused by a preceding
methotrexate treatment as has been described
earlier (7).
Discussion
Serum S'-nucleotidase was first reported to rise earlier
than alkaline phosphatase in cancer patients by Van der
Slik et al. In addition 5'-nucleotidase reacts more
strongly than does alkaline phosphatase (7, 1). This
was confirmed later by Schwartz (16). Therefore as a
monitor of neoplasm in the liver alkaline phosphatase
has lost most of its significance. Alkaline phosphatase
is more useful in the follow up of either recalcification
of the osteolytic areas (bone repair) or malignant
osteoblastic processes. The present study was undertaken
to investigate: a) whether γ-glutamyl transpeptidase
assays could give additional information to that provided
by the assay of other enzymes in current use and b)
whether γ-glutamyl transpeptidase could replace one
of these enzymes without losing diagnostic information.
Comparison with S'-nucleotidase, but not with alkaline
phosphatase, in view of the advantages cited above
seemed to us a logical approach.
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The results of this study indicate that γ-glutamyl trans-
peptidase does not have a sensitivity that exceeds that
of 5'-nucleotidase in the sense that it should rise
earlier. It may however show stronger elevations than
5'-nucleotidase and for this reason it may replace
5'-nucleotidase in untreated patients. This restriction is
necessary in view of the variable changes of 7-glutamyl
transpeptidase as a response to hepatotoxic therapy.
These changes due to hepatotoxity can be so strong that
they may mask any change of γ-gjutamyl transpeptidase
that reflects the course of a malignant process in the
liver. Hepatic injury during therapy may cause ele-
vations of 5'-nucleotidase too, but they are usually
small. In this respect advantage can be taken of the
fact that alanine aminotransferase reacts quite insensi-
tively to malignant processes of the liver but strongly
to hepatotoxic injury. Accordingly the assay of alanine
aminotransferase may help to differentiate a rise of
S'-nucleotidase level caused by progression of malignant
processes in the liver from one caused by hepatotoxic
injury due to the therapy (7, 1). Such a possibility does
not exist for 7-glutamyl transpeptidase. It may very
well be possible that elevations of γ-glutamyl trans-
peptidase due to hepatotoxity are not accompanied by
an increase of alanine aminotransferase. Consequently,
problems in the interpretation of γ-glutamyl trans-
peptidase values in treated patients will arise especially
if γ-glutamyl transpeptidase values change without
a concomitant change of alanine aminotransferase.
These facts in our opinion argue against a replacement
of S'-nucleotidase by γ-glutamyl transpeptidase in
cancer patients under treatment. Because of the greater
sensitivity of S'-nucleotidase than alkaline phosphatase
to liver malignancy the situation of an alkaline phospha-
tase being more elevated than S'-nucleotidase is a strong ,
indication that bone phosphatase is present in the serum
investigated. Thus a combined assay of both alkaline
phosphatase and S'-nucleotidase permits us in some
cases to establish the nature, of the elevated level of
alkaline phosphatase assays without electrophoretic
examination (1). Replacement of S'-nucleotidase by an
enzyme like γ-glutamyl transpeptidase that can some
times be elevated more strongly, may reduce the number
of cases in which the nature of elevated alkaline phos-
phatase in cancer patients can be established by the
assay of a liver-specific enzyme.
Taking the above facts into consideration we incline to
the following conclusion. The diagnostic significance of
γ-glutamyl transpeptidase in cancer patients lies pri-
marily in the information that is presented when normal
values are found. Normal values of γ-glutamyl trans-
peptidase mean that the liver damage of the patient
is minimal during the therapeutic treatment. Normal
values of γ-gl tamyl transpeptidase, especially when
found in consecutive assays combined with other
liver tests such as S'-nucleotidase, indicate with high
probability that liver metastases are absent. Following
a classification proposed in earlier report (1) yrghitamyl
transpeptidase belongs to group II (serum enzymes
which may increase both in cases of liver metastases
and in cases of toxic damage of the liver). To this group
belong aspartate aminotransferase and glutamate
dehydrogenase. In view of its sensitivity γ-gjutamyl
transpeptidase may rather replace these enzymes than
S'-nucleotidase in the follow up of cancer patients.
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